- Quarterly
- Annual
- TTM
-
Export .csv
-
Download Image
-
Copy link
-
Embed code
Share URL
Bar Chart preview
NewAmsterdam Pharma Company N.V. Research and Development (R&D;) Expenses is USD 153.73 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 3.49% change year over year. Research and development (R&D;) expenses are the costs associated with the development of new products, technologies, or improvements to existing products. NewAmsterdam Pharma Company N.V. Research and Development (R&D;) Expenses for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 148.54 M, a 36.85% change year over year. NewAmsterdam Pharma Company N.V. Research and Development (R&D;) Expenses for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 108.54 M, a 197.47% change year over year. NewAmsterdam Pharma Company N.V. Research and Development (R&D;) Expenses for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 36.49 M.
Embed chart view
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max